Contact Investors Careers Support Search English Model-informed Drug Development Data and Informatics Regulatory and Access Resources Company Home / Evidence, Value & Access / US Managed Markets Are you entering the stormy waters of US commercialization? US Managed Markets Charting the course to optimize value and access Navigating the complex forces that shape US managed markets has become ever more challenging. Success requires trusted market experience, deep scientific expertise, and sharp commercial intelligence. At Certara, our mission is to be your partner – developing proven value and access strategies based on timely and insightful evidence. You can count on a 20-year track record of delivering strategies that optimize your asset’s value to deliver access by payers, preference by HCPs and use by patients. Evidence-driven pricing and reimbursement strategy Identifying and navigating market access hurdles begins with understanding the clinical and market access landscape and requires research-based identification and refinement of key value drivers. We partner with our clients to develop comprehensive and early value assessments, and to prepare for launch with optimal price and coverage: Count on reliable primary insights from a vetted network of US formulary and distribution decision-makers, the Certara Compass Panel Anticipate and overcome coverage, coding, and payment hurdles Position optimal value messages to a variety of US market stakeholders Leverage qualitative & quantitative pricing studies, supported by deep expertise in gross-to-net modelling and value-based contracting Utilize strategic decision-making tools to answer future reimbursement and distribution scenarios in competitive categories as markets evolve Strengthen your value platform today Innovator Strategy and Investor Due Diligence Certara guides innovators in substantiating their market value for financing or partnering deals. We helped biotech clients create $44B in value for their investors through out-licensing of assets, IPOs, and acquisitions since 2018. On the buy-side, we are supporting high-stakes due diligence rounds, assessing commercial opportunities totaling around $2-3B every year. Benefit from our wide in-house therapeutic expertise to pressure-test registration, reimbursement, and commercialization assumptions Obtain strategic, impartial, and dependable assessments – validated by scientific expertise, data analytics, and validation with KOL and payer decision-makers Rely on rapid turnaround for tight due diligence timelines. Back up your deal structures with our quantitative net revenue forecasting, adjusting for critical pricing and access scenarios across key payer types Contact us for rapid due diligence assessments Value Frameworks and ICER- Assessments Demands for real-world evidence are increasing among all stakeholders, spurring payer expectations to see unique product value demonstrated within structured value frameworks, such as NCCN, ASCO or ICER. Many US payers refer to ICER assessments to support their formulary evaluation processes. Translate value strategies into multi-level response playbook of market access, HEOR, and communications tactics Set up and initiate an organizational readiness platform to enable your comprehensive ICER response Identify likely scenarios and pricing evolutions following new ICER reviews and corresponding competitive activity Read our latest ICER research Our Team Maximilian Vargas Sr. Director, US Access Strategy Maximilian Vargas, PhD MBA, is a Senior Director, US Access Strategy and Account Management within Certara’s Evidence and Access Group since 2012. He brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products. Resources Evidence and Access Overview BROCHURE Reimbursement and Launch Planning CASE STUDY Early Value Assessment and Due Diligence CASE STUDY Certara Announces Series of White Papers on Disruptive Trends in U.S. Market Access PRESS RELEASE The Escalating U.S. Policy Environment WHITE PAPER Innovative Financing for Novel Therapies WHITE PAPER The Rise of Cost Effectiveness Considerations in the US WHITE PAPER Key Trends in U.S. Specialty Pharmacy WHITE PAPER Services Anonymization and Redaction Cell and Gene Therapy Clinical Pharmacology Clinical Pharmacology Study Stewardship Complex Biologics Decision Analytics and Modeling Document Quality and Management Drug Development and Regulatory Strategy eCTD Authoring Templates French SNDS Data Access and Analysis See more Software PHOENIX™ PK/PD PLATFORM v 8.3 Phoenix WinNonlin Simcyp PBPK Simulator Quantitative Systems Pharmacology D360 Scientific Informatics Platform Integral Data Repository BaseCase Value Communication Software CODEx & Clinical Trial Outcomes Databases GlobalSubmit eCTD Submissions Software Phoenix WinNonlin Validation Suite See more Resources Articles Blogs Best of Blogs 2020 Case Studies Certara in the Press Certara University Certification Program Conferences Knowledge Base Podcasts See more Company Careers Certara Code of Conduct Contact Certara Leadership Legal Locations News Our Story Partners Privacy Center See more English Privacy Center Legal Copyright © 2020 Certara, USA. All rights reserved. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Accept All Cookies